Triple-Negative Breast Cancer (TNBC) Recruiting Phase 2 Trials for Paclitaxel (DB01229)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02315196Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast CancerTreatment
NCT01750073Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast CancerTreatment